Cargando…

MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama

BACKGROUND: The association involving mismatch repair (MMR) genes, molecular subtype and specific immune cell group in tumor microenvironment has been focused by more recent studies. Its prognosis value in lung adenocarcinoma (LUAD) neoadjuvant chemotherapy remains elusive. METHODS: The correlation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Liangliang, Hua, Hujia, Jiang, Xingyu, Xu, Xintian, Bai, Hua, Qian, Li, Duan, Jianchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243005/ https://www.ncbi.nlm.nih.gov/pubmed/37280528 http://dx.doi.org/10.1186/s12885-023-10905-3

Ejemplares similares

Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma
por: Liu, Tingting, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis
por: Chai, Yue, et al.
Publicado: (2022)

Acquired resistance to immunotherapy in MMR-D pancreatic cancer
por: Hu, Zishuo Ian, et al.
Publicado: (2018)

Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report
por: Zhang, Mai, et al.
Publicado: (2022)

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
por: Dai, Fuqiang, et al.
Publicado: (2022)

Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy
por: Groenewold, M.D., et al.
Publicado: (2022)

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

Immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line treatment of PD‐L1‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer: An updated systematic review and meta‐analysis
por: Chai, Yue, et al.
Publicado: (2022)

Measles, misinformation, and risk: personal belief exemptions and the MMR vaccine
por: Bowes, Johnathan
Publicado: (2016)

Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
por: Zhang, Yuguo, et al.
Publicado: (2022)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma
por: Chen, Mu, et al.
Publicado: (2022)

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2022)

Improving health literacy with mumps, measles and rubella (MMR) vaccination: comparison of the readability of MMR patient-facing literature and MMR scientific abstracts
por: Downey, Tina, et al.
Publicado: (2022)

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach
por: Versluis, Judith M, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2023)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Monitoring early responses to neoadjuvant chemotherapy and the factors affecting neoadjuvant chemotherapy responses in primary osteosarcoma
por: Yu, Hong, et al.
Publicado: (2023)

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
por: Yang, Zhang-Ru, et al.
Publicado: (2020)

Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer
por: Jiang, Lin, et al.
Publicado: (2021)

Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer
por: Lin, Guang-Tan, et al.
Publicado: (2022)

Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy
por: Dal Buono, Arianna, et al.
Publicado: (2021)

Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer
por: Maletzki, Claudia, et al.
Publicado: (2019)

Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer
por: Du, Jun, et al.
Publicado: (2021)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy
por: Qu, Xiaogang, et al.
Publicado: (2022)

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy
por: Wu, Hui, et al.
Publicado: (2023)

The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency
por: Yunlong, Wu, et al.
Publicado: (2022)

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k26856479edbggd9vav0dkt74i